Arbutus Biopharma (ABUS) Non Operating Income (2015 - 2026)
Arbutus Biopharma (ABUS) posted quarterly Non Operating Income of $787000.0 for Q1 2026, down 32.91% year-on-year from $1.2 million in Q1 2025, and down 48.7% on a QoQ basis from $1.5 million in Q4 2025.
Arbutus Biopharma (ABUS) Non Operating Income (2015 - 2026) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Non Operating Income for 12 consecutive years, with $787000.0 the latest figure, recorded in Q1 2026.
- Quarterly Non Operating Income fell 32.91% year-over-year to $787000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (down 29.77% YoY) and the FY2025 annual result came in at $4.7 million, down 27.19% from the prior year.
- Non Operating Income declined to $787000.0 in Q1 2026 per ABUS's latest filing, from $1.5 million in the prior quarter.
- Over the last five years, Non Operating Income for ABUS reached as high as $1.8 million in Q2 2024 and fell as low as -$347000.0 in Q1 2022.
- A 5-year average of $1.0 million and a median of $1.2 million in 2025 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income surged 1655.42% — and 2025, when it tumbled 46.78%.
- Year by year, Non Operating Income stood at $630000.0 in 2022, then jumped by 127.78% to $1.4 million in 2023, then declined by 2.37% to $1.4 million in 2024, then advanced by 9.49% to $1.5 million in 2025, then slumped by 48.7% to $787000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $787000.0, $1.5 million, and $917000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - | 787,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 787,000.00 |
| Dec 31, 2025 | 1.53 Mn |
| Sep 30, 2025 | 917,000.00 |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Sep 30, 2023 | 1.45 Mn |
| Jun 30, 2023 | 1.29 Mn |
| Mar 31, 2023 | 1.07 Mn |
| Dec 31, 2022 | 630,000.00 |
| Sep 30, 2022 | 244,000.00 |
| Jun 30, 2022 | -83,000.00 |
| Mar 31, 2022 | -347,000.00 |
| Dec 31, 2021 | -525,000.00 |
| Sep 30, 2021 | -750,000.00 |
| Jun 30, 2021 | -745,000.00 |